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1. Background 
1.1 Chronic heart failure 
Heart failure (HF) is a clinical condition where the heart is not able to meet the tissue need 
for oxygen delivery. Many definitions have been utilized the last decades. Current definition 
from European Society of Cardiology states that HF is a syndrome in which the patients 
should have symptoms of HF, typically shortness of breath and/or fatigue, signs of fluid 
retention and objective evidence of an abnormality of structure or function of the heart at 
rest (1). The term chronic HF is applied for patients with persistent abnormalities of heart 
structure or function. Coronary heart disease is the most common cause of HF and accounts 
for the majority of patients (2). Other important causes include valvular disease, 
cardiomyopathy and hypertension.  
Chronic HF is a major public health issue with a prevalence of more than 23 million 
worldwide and is associated with significant morbidity and mortality (3;4). The incidence 
increases with age. Prevalence in the developed world is found to be about 1 % in the 
general population in persons aged around 50, rising to about 10 % in persons aged above 
80 (5;6). At 55 years of age the lifetime risk of heart failure is estimated to 33 % for men and 
29 % for women (7). Despite improvement in treatment options the last decades, the 
prognosis remains poor with 5-year mortality rates reported as high as 65 % (7).  
Studies and clinical trials have documented survival benefits from modern heart failure 
treatment including medication and various device therapies, in HF patients with reduced 
left ventricular ejection fraction (LVEF). The recent years, awareness on the HF syndrome 
with preserved LVEF has increased. These patients account for half the patients with HF. To 
date no effective therapies have proven to change the natural history of these patients.  
1.2 Chronic kidney disease 
Epidemiological research in kidney diseases was long hampered by lack of a common 
definition of chronic kidney disease (CKD). In 2002 the Kidney Disease Outcome Quality 
Initiative (K/DOQI) proposed a classification of CKD for diagnosis and risk stratification (8). 
CKD stages 1 and 2 were defined as signs of kidney damage in patients with a normal or 
slightly reduced glomerular filtration rate, while CKD stage 3-5 were defined solely based on 
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glomerular filtration rate (GFR), and these patients with GFR < 60 ml/min/1.73 m2 were all 
classified to have renal dysfunction (Table 1). 
Table 1: Definition of chronic kidney disease (CKD) stages according to the K/DOQI guidelines 
(8). 
CKD stage  
1 eGFR ≥ 90 ml/min/1.73 m2 + proteinuria or structural kidney abnormality 
2 eGFR 60-89.9 ml/min/1.73 m2 + proteinuria or structural kidney abnormality 
3 eGFR 30-59.9 ml/min/1.73 m2 
4 eGFR 15-29.9 ml/min/1.73 m2 
5 eGFR < 15 ml/min/1.73 m2 
 
Based on this classification increasing knowledge of the epidemiology and significance of 
chronic kidney disease have evolved. The prevalence of CKD has been estimated to be 11 % 
in the United States (9), and similar prevalence is found in the Norwegian population (10). 
Furthermore, the prevalence in the United States increased by 30% from 1990 to 2000 (11). 
More prevalent hypertension, diabetes mellitus and obesity partly explained the increase. In 
addition to increasing age, these are all important risk factors for development and 
progression of CKD. This raises concern about future increased incidence of end stage renal 
disease (ESRD) and other complications of CKD including increased cardiovascular disease 
(11;12).  
1.3 Cardiorenal associations 
Patients with ESRD are well known to suffer a high risk of cardiovascular morbidity and 
mortality, having more than 10-fold increased risk of cardiac death than age-/gender-
matched controls in the general population (13). Cardiovascular risk is shown to increase 
even in early stages of CKD (14-17). Death due to cardiovascular disease is much more 
common in patients within all stages of CKD than reaching ESRD needing renal replacement 
therapy (18). Multiple explanations may exist for the high cardiovascular risk in CKD patients.  
Traditional risk factors for cardiovascular disease, such as hypertension, diabetes mellitus, 
smoking and dyslipidemia are risk factors for CKD as well, and highly prevalent in this 
population (19). In the course of declining renal function, kidney specific risk factors for 
cardiovascular disease like accumulation of uremic toxins, inflammation, anemia, 
disturbances in calcium and phosphorous balance, lack of active vitamin D and sodium and 
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water retention among others, will contribute to left ventricular hypertrophy (LVH), chronic 
inflammation, accelerated atherosclerosis, extravascular calcifications  and endothelial 
dysfunction (20;21). CKD patients are also less likely to receive risk-modifying medication 
and interventions compared to non-CKD patients (22;23).  
Just like cardiovascular disease is prevalent in patients with renal disease, primary heart 
conditions are commonly associated with renal dysfunction (24-28). Reduced renal 
perfusion, often predisposed by microvascular and macrovascular disease in the context of 
the same vascular risk factors associated with cardiovascular disease, may hemodynamically 
affect kidney function in HF patients (21). Furthermore, neurohormonal activation, renal 
venous congestion and adverse effects of pharmacotherapies used in the management of 
HF, have been suggested as causes for the high prevalence of renal dysfunction in HF 
patients (29;30). Regardless the cause, impaired and worsening, renal function in patients 
with acute and chronic HF is associated with adverse outcomes and prolonged 
hospitalization (25;26;28;31). Even slight decrease in GFR is found to significantly increase 
mortality risk in patients with chronic HF (25;27).  
Combined heart and kidney dysfunction is common. Primary disorders of either kidney or 
heart often result in secondary dysfunction or injury to the other organ (32). A vicious circle 
with worsening renal and cardiac disease occurs, a condition with serious prognosis and high 
burden of symptoms. 
The cardiorenal syndrome (CRS) was earlier used to describe a relatively normal kidney that 
is dysfunctional because of a diseased heart, with the assumption that in the presence of a 
healthy heart, the same kidney would perform normally (33). The more recent recognition of 
the numerous negative effects of heart disease on kidney function and kidney disease on 
heart function led to a new definition of the CRS (29), dividing into 5 different subtypes of 
cardiorenal syndrome. (Table 2) 
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Table 2: Definition of cardiorenal syndrome (CRS) (21) 
Cardiorenal syndrome (CRS) 
general definition 
A complex pathophysiological disorder of the heart and the 
kidneys whereby acute or chronic dysfunction in one organ may 
induce acute or chronic dysfunction in the other organ. 
CRS type 1  
(acute cardiorenal syndrome) 
Abrupt worsening of cardiac function (e.g. acute cardiogenic 
shock or acute decompensation of chronic heart failure) leading 
to kidney injury. 
CRS type 2  
(chronic cardiorenal syndrome) 
Chronic abnormalities in cardiac function (e.g. chronic heart 
failure) causing progressive chronic kidney disease. 
CRS type 3  
(acute renocardiac syndrome) 
Abrupt worsening of renal function (e.g. acute kidney failure or 
glomerulonephritis) causing acute cardiac disorder (e.g. heart 
failure, arrhythmia, pulmonary edema). 
CRS type 4  
(chronic renocardiac syndrome) 
Chronic kidney disease (e.g. chronic glomerular disease) 
contributing to decreased cardiac function, cardiac hypertrophy 
and/or increased risk of adverse cardiovascular events. 
CRS type 5  
(secondary cardiorenal syndrome) 
Systemic condition (e.g. diabetes mellitus, sepsis) causing both 
cardiac and renal dysfunction. 
 
1.3.1 Cardiorenal syndrome type 2. 
 
Figure 1: Cardio Renal Syndrome type 2. Ronco et al. Contrib.Nephrol. 2010 (21) 
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The present study included patients with chronic HF and thereby investigates topics related 
to cardiorenal syndrome type 2 (Figure 1). Impaired kidney function in patients with chronic 
HF is associated with adverse prognosis and even slight decreases in estimated GFR (eGFR) 
significantly increase mortality risk (27). Much of our knowledge on the relationship 
between HF and renal function originate from selected patient populations in clinical trials or 
hospitalized patients. There is limited understanding of the pathophysiology of renal 
dysfunction even in advanced heart failure. Hemodynamic issues as venous congestion and 
reduced renal perfusion due to powerful vasoconstriction are considered important (34;35). 
However, neurohormonal activation including the RAAS and SNS, oxidative stress, 
comorbidities and pharmacological heart failure treatment have a role as cardiorenal 
connectors affecting renal function (35). The explanation for the impaired prognosis 
observed in patients with chronic HF and CKD is also incompletely understood. A higher 
burden of comorbidities, more severe vascular disease and worsened cardiac function may 
explain part of the alteration. Furthermore, large randomized trials that have shaped the 
treatment of chronic HF in the two last decades, have consistently excluded patients with 
significant renal disease.  Lack of evidence based clinical treatment may cause that patients 
with chronic HF and renal dysfunction are less likely to receive potential life-saving 
treatment (26), thereby altering prognosis. 
1.4 Anemia in heart failure  
Chronic heart failure is a syndrome with various pathophysiological consequences. 
Neuroendocrine, metabolic and immunological changes are identified as HF develops. 
Anemia has been recognized by clinicians in HF patients for decades, but has only recent 
years received attention with systematic research. CKD is a common comorbidity in HF 
patients with anemia. The kidneys are essential in the endogenous production of 
erythropoietin, and renal dysfunction may induce anemia in HF patients creating a vicious 
circle, termed the “cardio-renal-anemia syndrome” (36). In addition to renal dysfunction, 
anemia of chronic disease, iron-deficiency and hemodilution appears to be important 
etiologies of anemia in HF patients (37;38). Treatment with ACEi and ARB may also 
contribute to anemia as these agents may inhibit erythropoiesis (39). Depending on the 
definition used and population studied, the prevalence of anemia in HF patients varies from 
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9 to 69 % (40). Anemia is identified as an independent prognostic factor of mortality in HF 
patients (41) and hemoglobin levels are related to symptoms and quality of life (42). 
Increased myocardial workload due to hemodynamic and neurohormonal changes is a 
consequence of anemia, thereby inducing cardiac remodeling and left ventricular 
hypertrophy (LVH). This may partly explain the impaired prognosis of anemia in HF patients. 
Clinical trials investigating specific anemia treatment with erythropoiesis stimulating agents 
(ESA) and intravenous iron in HF patients with anemia have been promising in regard to 
symptoms and quality of life (43-45). Convincing data on mortality are missing and we do not 
yet know when to start anemia treatment, treatment goals and who will benefit from 
treatment. Actually, we don’t know if anemia is a mediator or just a marker of poor 
prognosis in patients with chronic heart failure. 
1.5 B-type natriuretic peptide in heart failure 
B-type natriuretic peptide (BNP) is secreted from the cardiac myocytes predominantly as a 
response to wall distension and stretching. In addition to mechanical stimuli, neurohormonal 
activation including the renin-angiotensin-aldosterone system (RAAS) and the sympathetic 
nervous system (SNS) can act on cardiac myocytes to modulate BNP synthesis and secretion 
(46;47). BNP leads to vasodilatation and natriuresis, and acts as an antagonist on the RAAS 
and SNS (47;48). Patient BNP secretion may be measured as serum levels of the bioactive 
hormone BNP or its inactive amino terminal fragment (NT-proBNP). BNP and NT-proBNP are 
highly correlated and may be assumed to provide the same information about cardiac 
production of natriuretic peptides (49;50). Both are established as sensitive diagnostic 
markers of HF, and elevated levels are strong independent predictors of mortality in HF 
patients (51).  
Renal dysfunction has been considered a confounding factor when evaluating the level of 
natriuretic peptides in HF patients. The kidneys are thought to be important in the clearance 
of both BNP and NT-proBNP, and levels are often elevated in patients with renal dysfunction 
even in the absence of clinical overt heart failure (52;53). Elevated natriuretic peptides in 
patients with renal dysfunction may therefore be a result of accumulation due to reduced 
renal clearance rather than a marker of cardiac disease.  
15 
 
The contribution of the kidneys in the removal of the natriuretic peptides is, however, 
controversial (54;55). CKD is associated with cardiovascular disease (29;56) and BNP 
elevation in asymptomatic patients with CKD has been shown to independently reflect 
ischemic heart disease and left ventricular hypertrophy (57;58). Thus, elevated BNP levels in 
heart failure patients with renal dysfunction might reflect increased cardiac production and 
not exclusively decreased renal clearance. As renal dysfunction is common in HF patients 
(59), the uncertainty of the interpretation of the natriuretic peptides in patients with renal 
dysfunction limits the use in clinical practice. 
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2. Aims of the thesis 
 
1. Current knowledge on the prevalence and prognostic impact of renal dysfunction in 
HF patients is derived predominantly from hospitalized patients and highly selected 
study groups, and less is known about outpatients. We wanted to: 
 Describe the prevalence of chronic kidney disease in a Norwegian outpatient 
population with heart failure.  
 Evaluate the prognostic impact of renal dysfunction and identify associated 
factors to renal dysfunction in this population.  
 
2. Convincing data on benefit of specific anemia treatment and who eventually will 
benefit from such treatment is still lacking. We wanted to:  
 Describe the prevalence and prognostic impact of anemia in Norwegian 
outpatients with heart failure and its relation to renal function.  
 Investigate if anemia is an independent prognostic variable also in patients with 
the worst prognosis. 
 
3. The natriuretic peptides are proven to be an important prognostic variable in chronic 
HF, but the use in patients with renal dysfunction is questionable as levels of the 
natriuretic peptides are increased in renal dysfunction. Our aim was to:  
 Analyze the prognostic impact of BNP and NT-proBNP in patients with renal 
dysfunction to investigate if the natriuretic peptides are reliable prognostic 
markers also in these patients. 
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3. Material and Methods 
3.1 Study Population 
The Norwegian Heart Failure Registry was initiated in October 2000 with the intent to collect 
data on outpatients attending office visits in heart failure clinics (60). By March 2011, 6,482 
patients were included and the number of participating clinics counted 24, situated in all 
regions in Norway. Cardiologists in cooperation with specially trained nurses run the heart 
failure outpatient clinics. Patients with heart failure of any etiology, New York Heart 
Association (NYHA) function class I-IV, diagnosed clinically according to guidelines from the 
European Society of Cardiology (1), were enrolled consecutively in the heart failure clinics. At 
the first visit (baseline) medical history, physical examination, echocardiography, laboratory 
results, and the medical management of heart failure were registered. After adjustment of 
medical therapy and undergoing an educational program, visit 2 was recorded. If required, 
additional clinical visits could be scheduled to ensure optimization of therapy before visit 2. 
Finally, visit 3 was planned to occur 6 months after visit 2. The chronology of visits and the 
number of patients that have attended the different visits by March 2011 are outlined in 
figure 2. Selected baseline characteristics of the population by March 2011 are presented in 
table 3.  
  
 
Figure 2: Flowchart of patients attending the registered visits and patients lost to follow-
up between the visits, in the 6482 patients included in the Norwegian Heart 
Failure registry by March 2011.  
Mortality data were retrieved from the Norwegian death registry kept by Statistics Norway. 
All participants provided written informed consent prior to inclusion in the database. Only 
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unidentifiable data were entered in the database. Permission for this analysis was granted 
from the National Data Inspectorate and the Regional Committee of Medical and Health 
Research Ethics. The clinical, echocardiographic and laboratory analyzes were performed 
locally at the different outpatient clinics. 
Table 3: Selected baseline characteristics of 6286 patients included in the Norwegian Heart 
Failure Registry stratified by estimated glomerular filtration rate (eGFR). 
 Valid data 
% 
Total 
 
N=6286 
eGFR<60  
ml/min/1.73 m2 
N=2453 
eGFR≥60  
ml/min/1.73 m2 
N=3753 
P-value 
Age (years) 100 69.5 (12.1) 75.2 (9.3) 65.9 (12.2) <0.001 
Male gender 100 71.2 % 64.2 % 75.8 % <0.001 
BMI (kg/m2) 88.1 26.3 (5.1) 25.8 (4.8) 26.6 (5.2) <0.001 
EF (%) 89.0 32.4 (11.3) 32.9 (11.9) 32.0 (10.9) 0.010 
Coronary heart disease 96.0 54.9 % 64.4 % 52.5 % <0.001 
Vascular disease  94.1 15.1 % 19.5 % 12.2 % <0.001 
Diabetes mellitus 94.2 18.7 % 22.9 % 17.8 % <0.001 
NYHA class 98.5    <0.001 
I  4.7 % 2.5 % 6.2 %  
II  43.2 % 35.8 % 49.2 %  
III  48.9 % 59.2 % 43.4 %  
IV  1.7 % 2.5 % 1.2 %  
eGFR (ml/min/1.73m2) 99.5 67.3 (24.1) 44.8 (11.2) 82.0 (18.1) <0.001 
Hemoglobin (g/dl) 90.1 13.8 (1.7) 13.3 (1.7) 14.1 (1.6) <0.001 
Use of RAAS blocking drugs 99.8 88.2 % 83.7 % 91.1 % <0.001 
Loop diuretic dose (mg/day) 95.9 56.9 (58.2) 76.8 (70.7) 43.8 (43.8) <0.001 
Use of spironolactone 99.9 23.9 % 29.2 % 20.3 % <0.001 
Use of β-blocking drugs 99.9 83.2 % 82.8 % 83.6 % 0.436 
BMI: body mass index, EF: left ventricular ejection fraction, vascular disease: earlier stroke or peripheral 
vascular disease, eGFR: estimated glomerular filtration rate, RAAS blocking drugs: use of ACE inhibitors or 
angiotensin receptor blocker, loop diuretic dose: daily furosemide equivalent dose.  
Data presented as mean (SD) for continuous variables and percentage for categorical variables. 
    
3.2 Definitions 
3.2.1 Renal function 
Renal function assessed as GFR, was estimated based on the simplified Modification of Diet 
in Renal Disease (sMDRD) prediction equation (61) and expressed as eGFR as follows: 
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eGFR (ml/min per 1.73 m2) = 186.3*(serum creatinine (mmol/l)) -1.154 *(age) -0.203 
      *0.742(Female)*1.212(Black) 
 
Renal dysfunction was defined as eGFR < 60 ml/min/1.73 m2. Renal function was stratified 
according to GFR limits in the K/DOQI guidelines (8) (Table 1). Patients with eGFR greater 
than 60 ml/min per 1.73 m² were stratified into CKD stage 1 and 2, despite lack of data on 
renal damage. Severe renal dysfunction was defined arbitrarily as eGFR ≤ 45 ml/min per 1.73 
m2 as the number of patients with CKD stage 4 and 5 were low. This was done prospectively 
to add statistical power to the severe renal failure group.  
3.2.2 Heart failure severity 
Heart failure was categorized as New York Heart Association (NYHA) functional class I-IV 
based on symptoms during varying activities (Table 4). NYHA functional class III was divided 
into class IIIa and IIIb; patients in NYHA class IIIb were not able to cover 325 meters during 
the 6-minute walk test performed at the local heart failure clinics. Advanced heart failure 
was defined prospectively as NYHA class IIIb or IV. 
Table 4: Definition of NYHA functional class 
NYHA  
functional class 
 
I Patient with cardiac disease but without resulting limitations of physical activity. 
II Patient with cardiac disease resulting in slight limitations in physical activity. 
IIIa Patient with cardiac disease resulting in marked limitation in physical activity.    
6 minutes flat walking distance more than 325 meters. 
IIIb Patient with cardiac disease resulting in marked limitation in physical activity.    
6 minutes flat walking distance less than 325 meters. 
IV Patient with cardiac disease resulting in symptoms during rest and discomfort 
during any physical activity. 
 
3.2.3 Anemia 
Anemia was defined according to the World Health Organization (WHO) guidelines as blood 
hemoglobin below 13.0 g/dl in men and below 12 g/dl in women (62). Hemoglobin levels 
were analyzed at the local heart failure clinics. Baseline anemia was defined as anemia at 
visit 1. Sustained anemia was defined as anemia at both visit 1 and visit 3. Transient anemia 
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was defined as anemia at baseline but not at the last visit, while patients with new onset 
anemia were not anemic at baseline, but anemic at the last visit. 
3.2.4 B-type natriuretic peptide 
The analyses on BNP and NT-proBNP were performed at the various hospitals using different 
assays. Natriuretic peptides analyzed with various methods are not necessarily comparable 
even when analyzing the same peptide (63). In order to take account of different reference 
values and methods, patients were allocated to BNP groups center-wise to be able to 
analyze the prognostic information of higher and lower levels of natriuretic peptides across 
centers. The BNP groups were defined by quartile limits in patients without renal 
dysfunction i.e. estimated glomerular filtration rate (eGFR) > 60 ml/min per 1.73 m2. Patients 
with eGFR ≤ 60 ml/min per 1.73 m2 were center-wise then assigned to BNP group 1 to 4 
according to their level of natriuretic peptides. Centers included had to have sufficient 
number of patients, arbitrarily set to 40 or more, analyzed with the same assay. Patients 
from 13 outpatient clinics were included in the analyses. The patients were stratified 
according to their BNP or NT-proBNP level measured at the last attended visit. The average 
NT-proBNP levels which were used to define the BNP groups at the different centers were 
for group 1 < 495 pg/ml, group 2 495-1006 pg/ml, group 3 1006-2180 pg/ml and group 4 > 
2180 pg/ml, while for  BNP < 91 pg/ml, 91-204 pg/ml, 204-504 pg/ml and > 504 pg/ml in the 
4 groups respectively. 
3.2.5 Other definitions 
A high proportion of the population was already treated with diuretics, RAAS blocking drugs 
and β-blockers at baseline. To differentiate between treatment intensity daily dose 
equivalents were calculated. Daily doses of loop diuretics were expressed in furosemide 
equivalents (bumetanide 1 mg = furosemide 40 mg). Doses of angiotensin converting 
enzyme inhibitors (ACEi) were expressed as enalapril equivalents per day (captopril 5 mg = 
ramipril 0.5 mg = lisinopril 1 mg = enalapril 1 mg). ACEi were more frequently used than 
angiotensin receptor blockers (ARB), and patients using ARB were excluded when analyzing 
ACEi daily dose in the baseline characteristics. Daily dose of β-blocker was expressed as 
metoprolol equivalents (bisoprolol 1 mg = carvedilol 5 mg = atenolol 10 mg = metoprolol 20 
mg). 
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Vascular disease was defined as previous stroke and/or peripheral arterial disease. The 
diagnosis of ischemic heart disease (IHD) as the cause of heart failure was based on clinical 
evaluation at the time of inclusion. 
3.3 Statistical analyses 
3.3.1 General statistics 
Analyses were performed using SPSS statistical software (SPSS inc. Chicago, IL, v.14.0-19.0). 
Level of significance was set to 0.05.  
Continuous variables were presented as mean ± standard deviation. Selected non-normally 
distributed continuous data were presented as median and interquartile range.  Categorical 
data were presented as percentages. Student T-test and analysis of variance (ANOVA) were 
used when comparing continuous data across categories of patients. For the same purpose 
Chi Square test was utilized on categorical data. Cases with missing data were deleted from 
the multivariate analyses. 
Multivariate linear regression was used to identify associated independent variables of renal 
function at baseline and predictors of change in GFR during optimizing heart failure 
treatment. The assumption of linearity of continuous variables were checked and verified 
and residual analyses were used to check for normal distribution and equal variance. 
Spearman’s test was used to check for multicollinarity, i.e. if pairs of independent variables 
were found to correlate to such a degree that they could not be simultaneously entered 
together in the regression analyses. 
Multivariate logistic regression was used to identify associated independent variables when 
the outcome variable was dichotomous. The assumption of linearity of the logit of the 
outcome for continuous variables entered into the logistic models, were checked and found 
to be adequately met (64). 
Kaplan-Meier plots were used to describe survival during the observation period in different 
patient groups. Log rank statistics identified differences between groups. 
22 
 
Multiple Cox regression analyses were performed to determine the association of different 
variables with all-cause mortality. For each Cox model the proportional hazard assumption 
was checked and found to be adequately met. 
Analyses on selected interactions were performed by entering product terms into the 
different regression analyses. 
3.3.2 Paper specific statistics 
3.3.2.1 Paper I 
The population was randomized into two equal sized samples: a model building sample 
where independent variables were identified, and a second sample to validate the 
independent variables identified in the model building sample. In the validation model only 
significant independent variables from the model building samples were included. Our study 
population was large enough to allow such analyses that served to improve the final model 
stability of the regression models.  
3.3.2.2 Paper III 
Nelson-Aalen plots were constructed to describe the change in hazard by length of follow-up 
time in patients with renal dysfunction within BNP group 1-3. This demonstrated that the 
assumption of proportional hazards were not met and led to separate Cox analyses on 2-
year all-cause mortality and all-cause mortality beyond 2 years of follow-up.  Figures were 
computed in STATA version 11.0 as the appearance and presentation of the figures were 
considered nicer using this software. 
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4. Summary of results 
4.1 Paper I 
The relationship between eGFR and all-cause mortality in outpatients with HF was 
investigated. Furthermore, factors associated with and predictive of impaired renal function 
were assessed. Renal dysfunction, defined as eGFR<60 ml/min/1.73 m2, was highly prevalent 
(44.8 %) at baseline. Estimated GFR was an independent predictor of all-cause mortality 
together with age and NYHA class. Lower eGFR was independently associated with higher 
age, female gender, lower hemoglobin level, more severe heart failure (NYHA class), 
comorbidities (hypertension and vascular disease) and medications at baseline 
(spironolactone and higher diuretic dose). Higher systolic blood pressure, lower hemoglobin 
levels and the use of spironolactone predicted worsening renal function during follow-up, 
while higher dose of diuretics tended to predict worsening renal function. 
4.2 Paper II 
The impact on all-cause mortality of anemia in outpatients with HF, and specifically its 
prognostic utility in patients with severe renal dysfunction or advanced heart failure, was 
investigated. Baseline anemia was present in 24 % and was a strong independent predictor 
of all-cause mortality. However baseline anemia did not predict mortality in patients with 
severe renal dysfunction or advanced HF. In the selected population with valid follow-up 
data after optimizing heart failure treatment, sustained anemia implied worse prognosis 
irrespective of renal function and NYHA class, whereas transient and new-onset anemia did 
not. 
4.3 Paper III 
The prognostic utility BNP and NT-ProBNP levels in HF outpatients with renal dysfunction 
was investigated and compared with HF patients with preserved renal function. The majority 
of patients with renal dysfunction had BNP levels in the highest BNP group (59.1%). Patients 
with renal dysfunction and BNP levels in the lower three groups had similar 2-year survival 
as patients without renal dysfunction and comparable BNP levels. Beyond two years of 
follow-up renal dysfunction predicted worse outcome irrespective of levels of natriuretic 
peptides.  
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5. Discussion 
5.1 Methodological considerations 
5.1.1 Study population and study design  
During the last decades an increasing number of medical patient registries have been 
established in Norway and the rest of the world. The ambition has been to continuously 
evaluate the treatment and outcome of defined patient groups in different treatment 
centers. The registries are organized as longitudinal observation of individual patients by 
recording course of treatment and outcome, thereby creating a continuously growing 
dynamic cohort reflecting real life management of a defined patient group. The Norwegian 
Heart Failure Registry was initiated in October 2000. Starting with 10 outpatient HF clinics, 
the number of participating clinics has continuously grown. The registry is now about to be 
given the status of a national quality registry, which will impose participation from all heart 
failure clinics in Norway.   
A crucial term in epidemiology is causality. Observational studies are not able to conclude on 
causality as associations found may be an effect of confounding variables and other 
systematic errors rather than being a cause of the outcome. Furthermore, selection of the 
subjects is a common problem in cohort studies. In the present study, patients attending 
outpatient heart failure clinics were included in the cohort. This is probably a selected heart 
failure population as institutionalized patients were not admitted and patients with 
advanced comorbidities, including advanced renal dysfunction, were treated in other 
specialist clinics. Patients with less severe heart failure may not have got the heart failure 
diagnosis or were not admitted to the outpatient clinics. Loss to follow-up was another 
concern in the present study as a considerable amount of patients did not attend visit 2 and 
3. The population that attended all visits differed significantly from patients who did not 
complete all visits, thereby weakening the reliability of the results from the follow-up 
analyses. Still another weakness concerning the registry cohort design was lack of clinical 
and laboratory records beyond visit 3. Change in important risk factors and habits were not 
detected as only all-cause mortality was registered beyond visit 3. As a consequence, the 
results in this study should be considered hypothesis generating rather than conclusive 
considering causality.  
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Experimental studies are considered the method of choice to investigate for causality. The 
randomized controlled trial (RCT) is designed to correct for all types of systematic errors, 
leaving the difference between the investigated groups to rely only on real effect of 
intervention or variation by chance (given by the p-value). However, experimental studies 
are highly consuming and not all questions are suitable to be answered by this study design. 
Furthermore, the studies are often carried out in highly selected patient populations, 
questioning the reliability of the results in the unselected population. In paper II this concern 
was illustrated when baseline anemia was found to be an independent marker of all-cause 
mortality, but not in patients with advanced heart failure or severe renal dysfunction. This 
interaction was not present in the selected population that attended subsequent visits 
where sustained anemia was an independent prognostic marker irrespective of NYHA class 
and level of eGFR. Thus, conclusions from experimental studies in highly selective 
populations are not necessarily transferable to the unselected population. 
Well performed observational studies are necessary to generate good hypotheses prior to 
planning and performing good experimental studies. Well-organized patient registries will 
most likely, be increasingly important in the future, as the number of registries and the 
number of patients enrolled continuously rises. 
5.1.1.1 Ethics 
The study was observational. The patients were not exposed to any extra treatment or 
additional examinations as a consequence of participating in the study. All participants 
provided written informed consent prior to inclusion in the database. Only unidentifiable 
data were entered in the database. Permission for this analysis was granted from the 
National Data Inspectorate and the Regional Committee of Medical and Health Research 
Ethics. 
The large set of data increases the possibility to find false statistically significant correlations 
and associations. The hypotheses and aims were defined prior to analyses to prevent 
publication of false positive results. 
All authors have taken sufficiently part in the work to be listed as authors. The research and 
methods have been continuously discussed in the research group. 
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5.1.2 Estimation of GFR by creatinine based formulas 
The definition and staging of CKD depends on the assessment of GFR, proteinuria and other 
markers of kidney disease. GFR cannot be measured directly. However, if a substance is 
present in stable concentrations in the plasma, is freely filtered in the glomerulus and 
neither secreted, reabsorbed, synthetized nor metabolized by the kidney the amount of that 
substance in the urine will equal the amount filtered in the glomerulus. Therefore, inulin 
clearance is considered an ideal method and gold standard of GFR measurement. Inulin 
clearance is however, demanding and difficult to use in daily practice. Alternative measures 
for estimating GFR have emerged including radionuclide technics of clearance of exogenous 
markers, 24-hour creatinine clearance or serum creatinine and cystatin C concentration, all 
having significant limitations in accuracy or availability. 
Equations to predict GFR from serum creatinine have been tested in a large number of 
studies. Relevant equations have been shown to give more valid estimates of GFR than 
serum creatinine alone (65). Both American (66) and European (67) guidelines state that GFR 
estimation formulas are superior to serum creatinine alone, recommending the use of the 
Modification of Diet in Renal Disease (MDRD) formula (65) or the Cockcroft-Gault (CG) 
equation (68). More than 90% of the estimates were within 30% of the measured GFR when 
using MDRD formula (65), and this formula is found to perform better than the CG equation 
(66). Still, both equations are inaccurate in individuals, and loose accuracy in patients with 
near normal range GFR (GFR> 60 ml/min/1.73 m2).    
All creatinine based formulas are dependent on calibration of the serum creatinine assay. 
The analysis of serum creatinine was standardized in Norway between 2002 and 2005 to 
adjust to common Nordic reference intervals (69). 
In patients with heart failure the MDRD formula was considered the most precise of the 
traditional creatinine based equations, especially in the lower ranges of GFR (70). The 
simplified MDRD (sMDRD) formula was slightly less accurate (70), but the easy accessibility 
in clinical practice by taking only serum creatinine, age, gender and ethnicity into account, 
makes it attractive to use. The sMDRD formula was used in our study to estimate GFR. The 
sMDRD equation tend to underestimate GFR in the near normal range of renal function (GFR 
> 60 ml/min/1.73 m2), and overestimate GFR in the lower ranges, thus, the observed 
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associations between GFR and covariates and outcome in our study could be 
underestimated. Our study population was large, thereby correcting for the inaccuracy of 
the equation in individuals. 
In paper 2, severe renal dysfunction was defined as eGFR < 45 ml/min/1.73 m2. This arbitrary 
stratification was done prospectively to increase statistical power to the group with the 
worst renal function. Few patients in the registry had CKD class 4 and 5, perhaps because 
these patients were treated in nephrology clinics. 
The chronic kidney disease epidemiology collaboration (CKD-EPI) equation was published in 
2009 in an effort to be more generalizable across various clinical settings than the MDRD 
formula (71). The new equation appear to be more accurate than MDRD and result in lower 
prevalence of CKD (72). However, this equation is still not validated in patients with heart 
failure, and was not available when the current study was planned.  
5.1.3 NYHA classification 
Severity of HF is commonly classified due to symptoms and exercise capacity using the New 
York Heart Association functional classification (NYHA class). The classification was 
developed in 1928, and the latest revision was presented in 1994 (73). Despite that NYHA 
classification is a rough and subjective classification system with large inter- and intra-
observer variability (74), it is proved to provide important prognostic information (75) and is 
applied routinely in clinical research.   
The user manual in the Norwegian Heart Failure registry defines the criteria of classification 
into NYHA class (Table 4). According to the user manual NYHA class III was subdivided into 
IIIa and IIIb based upon the patient’s ability to walk more or less than 325 meters during a 6-
minute walk test. NYHA class IIIb has been increasingly used to categorize patients with 
advanced heart failure as the original classification system is not refined enough to 
characterize the broad spectrum of patients with advanced heart failure. NYHA IIIb is meant 
to classify patients who are more ill than the overall group of class III patients, but not as ill 
as those who are NYHA class IV. However, NYHA class IIIb has no consensus definition in the 
medical literature, and its use in clinical practice and research has been criticized (76). In the 
Norwegian Heart Failure Registry the stratification into NYHA class was done locally at the 
outpatient clinics, and no data on distance achieved during the 6-minute walk test was 
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available.  In paper II, NYHA class IIIb and IV defined patients with advanced heart failure. 
This arbitrary classification was done prospectively to ad statistical power to the subgroup of 
patients with the most symptomatic heart failure. As the number of patients presenting 
NYHA class IV was low (1.6%) and the majority of patients were classified to NYHA class III 
(50.1%) a subclassification was required. A stepwise increase in risk of mortality with 
increasing NYHA class in our study supported the classification used (Figure 3).  
Despite the subjective nature of the NYHA classification system, our study confirms its 
strength as a prognostic variable in the heart failure population. 
 
 
 
 
Figure 3: Kaplan-Meier survival plot in 4069 outpatients with heart failure stratified by New 
York Heart Association (NYHA) functional class at baseline. Log –rank statistics = 158.03 
(p<0.001) 
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5.1.4 Definition of anemia 
Anemia was defined according to the World Health Organization (WHO) guidelines as blood 
hemoglobin below 13.0 g/dl in men and below 12.0 g/dl in women (62). The definition was 
proposed by a WHO expert committee over 40 years ago, based on very few data  using 
methods that were inadequate (77). Knowledge from more recent population studies 
suggest that the hemoglobin level for defining anemia should be adjusted for age, gender 
and ethnicity. Furthermore, the WHO definition generally underestimates the prevalence of 
anemia if the reference value should describe a hemoglobin level above which 95% or 97.5% 
of the normal subjects are included (77). In older patients and in blacks the WHO definition 
may overestimate the prevalence of anemia (77). Still the WHO definition is the most 
frequent definition of anemia used, also in the heart failure population (41). 
5.1.5 Measurement of the natriuretic peptides 
The natriuretic peptides were analyzed at the different participating centers using different 
assays. Patient BNP level may be measured either as the bioactive hormone BNP or the 
inactive amino terminal fragment (NT-ProBNP). BNP and NT-ProBNP are different 
biomarkers with different kinetics. While secretion is similar in response to appropriate 
stimuli (78), BNP is cleared from the circulation through proteolytic cleavage by neutral 
endopeptidase 24.11 (NEP) and binding to the clearance receptor natriuretic peptide 
receptor-C (NPR-C) (47). NT-ProBNP is not cleared by NPR-C and has a longer half-life than 
BNP (78). The majority of centers in the Norwegian Heart Failure Registry measured NT-
ProBNP. Even within analyzes of the same peptide, different assays exists using different 
epitopes and with different epitope specificity. No applicable conversion factors exist 
between the different analyzes and assays. Hence, the levels of natriuretic peptides between 
the centers were not directly comparable. To overcome this methodological problem, BNP 
groups were created center-wise defined by quartile limits in patients without renal 
dysfunction i.e. eGFR > 60 ml/min/1.73 m2. Thereby, it was assumed that the populations at 
each center were comparable and that this method classified the patients into 4 groups with 
increasing levels of natriuretic peptides irrespective of assay used and peptide measured. To 
check if these assumptions were fulfilled treatment center was entered into the multivariate 
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models in Paper III and this did not affect our results. Neither was treatment center an 
independent predictor of all-cause mortality. Furthermore, interaction analyses did not 
detect any differences between BNP and NT-ProBNP as the measured peptide. Therefore, 
we assumed that center-wise allocation into BNP groups would provide similar information 
irrespective of whether BNP or NT-ProBNP were used at the different centers. However, we 
cannot exclude the possibility that difference may exist between peptide analyzed and assay 
used.     
Both BNP and NT-ProBNP are inversely related to GFR (79;80). Since both NEP and NPR-C are 
highly expressed in renal tissue and renal filtration and passive excretion might be 
responsible for some BNP clearance as well (78), higher levels in patients with renal 
dysfunction could be explained as an effect of accumulation (79;81). NT-proBNP level have 
been reported to be more affected by GFR (58;79). This could have affected our results if 
more patients with renal dysfunction were classified to higher BNP groups when NT-ProBNP 
was measured compared to BNP. However, Van Kimmenade et al. (54) have found BNP and 
NT-ProBNP to be equally dependent on renal function for their clearance, and both peptides 
are found to be similarly useful prognostic tools in renal patients (82;83). Again, no 
significant interaction between BNP and NT-ProBNP in the Cox-analyzes supported that 
patients with renal dysfunction were categorized into BNP groups independently of peptide 
analyzed. 
Last visit BNP/NT-ProBNP levels were used to categorize patients into BNP groups. At visit 2 
in the heart failure registry the treatment should have been optimized, and all patients did 
not complete all visits in the registry. Optimizing heart failure treatment is known to affect 
BNP levels (84-87). Therefore, the last registered visit was thought to represent the most 
standardized point zero for analyses of natriuretic peptides and length of follow-up. 
Only 2076 patients, accounting for about 1/3 of the registry population, were allocated to a 
BNP group and included in the analyses in Paper III. Measurement of the natriuretic peptides 
has been increasingly available in Norwegian heart failure outpatient clinics since the start of 
the heart failure registry in the year 2000. Most patients included the first years had no 
registrations on natriuretic peptides, while most patients included the later years had 
multiple registrations. Furthermore, in order to categorize patients into BNP groups based 
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on quartile limits in patients without renal dysfunction, each center had to have a sufficient 
number of patients analyzed with the same method to be included in the analyses. Patients 
from 13 of the participating centers were included, excluding small centers, centers that 
changed their method of analysis during the period or introduced methods for analysis or 
registration of natriuretic peptides more recent years. The population with valid BNP 
registrations differed in baseline characteristics significantly from the rest of the registry 
population by having shorter follow-up time, younger age, higher systolic blood pressure, 
higher se-sodium level, lower ejection fraction and less IHD. Thus, selection bias, meaning 
that registrations of last visit BNP/NT-ProBNP were more likely in certain patients, cannot be 
excluded. 
5.1.6 Statistical considerations 
5.1.6.1 Assumptions of the regression analyses 
Statistical models are approximation of data. In linear regression, the linear assumption does 
not mean that all observations fit a linear model; it means that a line is a good 
representation of the association between variables. Likewise, logistic and proportional 
hazard regression analyses are theoretical models with assumptions which have to be 
fulfilled if the analyses should be valid. 
For every regression model presented in the papers the assumptions of each model were 
checked. As a consequence some variables were transformed to fit the assumptions. In 
paper III, the assumption of proportionality was not met in the Cox analysis that analyzed 
the prognostic effect of lower BNP levels in patients with renal dysfunction. The analyses 
were then split into the first 2 years of follow-up and beyond 2-years of follow-up to fulfill 
the assumption of proportionality. 
5.1.6.2 Variable selection techniques 
The database included a large number of variables and a decision which variables to enter 
into the different regression models had to be made. The sample size in the current study 
was large and did not restrict the number of variables entered into the models. However, a 
manageable number of independent variables necessary to estimate outcome was desired.  
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Automatic variable selection techniques available in the statistical software use statistical 
criteria to decide which and in what order, the variable should enter the model. The forward 
selection technique is desirable when sample size is small to minimize the number of 
variables entered into the model. However, forward selection does not deal well with 
suppresser effects. Likewise, a backward selection technique has a potential of not entering 
important confounders into the model. The variable selection in this study was mainly 
carried out by a combination of theoretical understanding and the univariate statistical 
relation with the outcome. In addition selected variables were not entered into regression 
models because of low numbers of valid data. Modest confounding variables may therefore 
have been missed in our analyses. Furthermore, analyses were restricted to existing 
variables in the heart failure registry.    
5.1.6.3 Interactions 
Still another assumption of multivariate regression analyses is that the independent 
variables should have additive effect on the outcome. Interactions are present when the 
variables are not additive, but rather something greater or less than additive. The regression 
models calculate the best coefficient for each variable for the sample as a whole, this may 
not be best for every subgroup of subjects.  
In paper II, checking for interactions were predefined as one of the aims of the study. 
Knowing that anemia was an independent marker of all-cause mortality, the aim was to 
investigate if this was valid also in patients with severe renal dysfunction or advanced heart 
failure. The conclusion was that there was a significant interaction and that anemia was not 
an independent prognostic marker in these patients. This may indicate that anemia should 
be interpreted different in different subjects. 
In the current study a large number of variables were analyzed, and thus a huge amount of 
potential interactions may exist in the dataset. It would have been almost impossible to 
identify all significant interactions in the present analyses, and some statistically interactions 
are difficult to interpret clinically when recognized. Furthermore, with increasing number of 
interaction analyses it is likely that at least one of them will be statistically significant, 
thereby increasing the risk for type I errors, i.e. rejecting the null hypothesis of no 
interactions when the null hypothesis is really true. As a consequence, interaction analyses 
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by product terms were performed when they were thought to be theoretically important. All 
interaction analyses performed where described in the methods section of each paper.     
5.1.6.4 Validation sample 
In paper I the regression analyses were performed in two steps to strengthen the final model 
stability. This type of analysis is rarely done in medical research. We observed that the 
effects of the independent variables in the regression models were, on average, about 30% 
lower in the validation sample than in the initial model building sample. This observation is 
not surprising to statisticians (88) and indicates that regression models without validation 
may overestimate the effect of individual variables and thus, could lead to faulty 
conclusions. 
5.2 Discussion of results 
5.2.1 Paper I 
5.2.1.1 Prevalence and consequence of impaired renal function in outpatients with 
HF 
Nearly half of outpatients with HF attending Norwegian heart failure clinics had significant 
reduction in renal function i.e. eGFR < 60 ml/min/1.73 m2. In accordance with other studies 
(25-27;31), this confirmed that renal dysfunction is highly prevalent in the HF population. 
Furthermore, GFR was verified as a strong independent predictor of all-cause mortality 
(24;25;27;89). The proportion of patients in CKD stage 4 and 5 (i.e. eGFR< 30 ml/min/1.73 
m2) was lower than expected from comparable studies (25;26;31). This might indicate that 
the prevalence of renal dysfunction was actually underestimated as those with the most 
advanced renal failure would be more likely to attend a renal clinic rather than a HF clinic in 
Norway. Nevertheless, cardiorenal associations are common and awareness of its 
consequences and how to preserve renal function ought to be important for every physician 
dealing with heart failure patients. 
5.2.1.2 Medications associated to GFR in HF patients 
The relationship between CKD and HF is not fully understood (29).  There is limited 
understanding of the pathophysiology of renal dysfunction even in advanced heart failure. 
Hemodynamic issues like venous congestion and reduced renal perfusion are important 
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(34;35).  A 25 % reduction in cardiac output is shown to at least halve the renal perfusion 
(90). The positive effect on GFR by cardiac resynchronization therapy (91) underlines the 
importance of hemodynamic issues in cardiorenal syndrome type 2 and should motivate 
optimized heart failure treatment in these patients. However, medications used in heart 
failure therapy may potentially influence renal function. Lack of evidence in patients with 
renal dysfunction and fear of further decline in GFR may contribute to that HF patients with 
impaired kidney function are less likely to be described efficacious therapies. Evolving data 
though, indicate that patients with renal dysfunction have better outcomes if they receive 
these medications (25;26). In our study, close to 90% of patients received RAAS-blocking 
agents, and nearly 80% used β-blocking drugs at baseline. This is higher than in comparable 
studies (25;26;31), indicating that our study population was reasonably well treated at 
inclusion. Still the treatment was intensified during the follow-up period to the last visit in 
the registry (60).    
At baseline a wide range of variables were found to be associated with GFR. Increasing age, 
female gender, history of hypertension and previous stroke or vascular disease were all 
independently related to lower GFR. More interestingly, the potentially modifiable factors: 
higher NYHA class, lower hemoglobin level, higher loop-diuretic dose and the use of 
spironolactone were independently associated with worse renal function at enrollment in 
the study. Use of β-blocking drugs and treatment with RAAS blocking drugs were not 
independently associated with GFR. Associated factors at enrollment are not easy to 
evaluate as they could be a consequence as well as a cause of renal dysfunction.  However, 
the results may be read as that Norwegian HF patients are likely to be prescribed RAAS- and 
β-blocking drugs irrespective of renal function. Diuretics, however, were prescribed at a 
higher degree among patients with impaired kidney function at baseline. Higher doses of 
loop diuretics are required in patients with renal insufficiency than in those with normal 
renal function to achieve the same diuretic response (92). This may explain the association 
between loop diuretic dose and GFR found at baseline. More surprisingly we found that the 
use of spironolactone was independently related to declining GFR. Despite convincing data 
regarding prognostic effect in patients with advanced systolic HF (93), concern has been 
raised about worsening renal function and hyperkalemia with this treatment (94). Treatment 
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with spironolactone is actually considered contraindicated in patients with renal 
dysfunction.  
During a median follow-up time of 9 months whereas the heart failure medication was 
optimized and the patients underwent an educational program, changes in GFR were 
analyzed in a subpopulation of the registry.  While mean change in eGFR was modest, 1/3 of 
the patients experienced a clinical significant drop in GFR of more than 10 %. These patients 
would be expected to carry a worse prognosis (28;95). Increased blood pressure, lower 
hemoglobin levels and the use of spironolactone predicted deterioration of renal function, 
while a trend was found for intensified dosage of loop-diuretics.  
HF patients with renal dysfunction have largely been excluded from the large clinical trials 
that have established modern HF treatment. RAAS blocking drugs have been a concern as 
they interfere with the kidney’s regulation of glomerular filtration pressure and are a major 
risk factor for acute kidney injury in situations where kidney perfusion is affected. However, 
the same drugs have important renoprotective properties by slowing the decline in GFR, 
preventing diabetic nephropathy, reducing proteinuria and reducing risk of dialysis (96;97). 
Actually, growing evidence exists that patients with HF and renal dysfunction may benefit 
more from ACEi and ARB than patients with HF alone (96). In our study change in intensity of 
RAAS blocking drugs, together with β-blockers, did not predict changes in GFR during a 
median 9-month of follow-up. This may indicate that fear of worsening renal function by 
introducing or intensifying these treatments is exaggerated. 
Treatment with spironolactone was an independent predictor of declining renal function 
during follow-up. It is a concern that the group of patients proven to benefit from the 
treatment (the most advanced HF), is the group of patients with the lowest GFR and at 
highest risk of the feared adverse effects of hyperkalemia and worsening renal function (94). 
Careful selection of patients and close monitoring seems warranted for HF patients treated 
with spironolactone. 
Loop-diuretics are widely used in HF, but their effect on outcomes has not been fully 
evaluated in large clinical trials. No doubt, diuretics are efficacious in relieving clinical 
symptoms of shortness of breath and signs of peripheral edema. Decongestion may also 
improve cardiac performance by reducing left ventricular preload. However, diuretic 
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activation of neurohormonal systems like RAAS and SNS may be associated with increased 
morbidity and mortality (98-102). Influence on GFR may explain part of this association as 
neurohormonal activation is important in the pathophysiology of both HF and progression of 
CKD. Higher dose of loop diuretics was strongly associated with low GFR in our study. This is 
known from other studies (103). Furthermore, higher doses of loop diuretics tended to 
predict further decrease in GFR, though it did not reach statistical significance in the 
validation sample.  Neurohormonal activation in combination with risk of volume depletion 
with excessive use of diuretic, may affect renal perfusion and GFR in HF patients. Conversely, 
diuretic therapy may favorably affect renal and tubular function by decreasing congestion 
(104). The definitive role of loop diuretics remains unclear and they appear as a two-edged 
sword with negative consequences on heart and renal function by both too low and too high 
doses. A large randomized trial is longed for, but probably will never occur. Hopefully, new 
therapies will emerge that demonstrate effective decongestion with less neurohormonal 
activation (105). 
5.2.2 Paper II 
5.2.2.1 Epidemiology of anemia in HF patients 
Baseline anemia was common in our registry patients. Renal dysfunction, activation of 
neurohormonal and inflammatory responses, malnutrition, iron deficiency, drug effects and 
bone marrow hyporesponsiveness seem to contribute to the development of anemia in HF 
patients (38;39). Estimates of anemia prevalence in HF patients have varied widely 
(40;106;107), much due to different definitions of anemia used and differences in study 
population. Hospitalized patients with the highest degree of accompanying diseases and 
congestion tend to have the highest prevalence, whereas highly selected clinical trial cohorts 
have the lowest prevalence as patients with comorbidities are largely excluded from clinical 
trials. Compared to other outpatient HF populations, our baseline prevalence of 24% was 
coincident. 
5.2.2.2 Prognostic impact of anemia in patients with HF and renal dysfunction 
Baseline anemia was strongly associated with all-cause mortality in our population. Median 
survival was more than 3 years shorter in anemic, compared to non-anemic patients. Thus, 
anemia - independent of cause - identified patients with a poor prognosis and should alert 
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the clinician to the need for particular attention. After adjustment for a large range of 
confounders, anemia remained a strong independent risk factor for all-cause mortality. The 
mechanisms behind the increased mortality risk in anemic HF patients are not completely 
understood. Increased cardiac work, neurohormonal activation, reduced renal perfusion and 
salt and water retention could be consequences of anemia which might affect prognosis 
(107). 
Both lower GFR and higher NYHA functional class were independently associated with 
anemia at baseline. The simultaneous presence of anemia, HF and CKD is referred to as the 
cardio-renal-anemia syndrome (36;108). Anemia can cause or worsen CKD and HF, at the 
same time it may be a consequence of either of the 2 conditions as well (108). As 
epidemiological data have suggested an inverse relationship between serum creatinine level 
and the prognostic information of anemia in HF patients (41), we wanted to evaluate the 
prognostic impact of baseline anemia on all-cause mortality in the subgroups of HF patients 
with the most advanced NYHA class and most severe renal dysfunction. Strikingly, we found 
that anemia was not an independent predictor of mortality in these patients. This might 
indicate that the ill prognosis in these patients accounts for a greater proportion of the 
mortality risk than anemia, but also may indicate that lower hemoglobin is somewhat 
compensatory in patients with the worst prognosis by lowering blood viscosity and thereby 
potentially reduce the risk of thromboembolic events (109) and improve tissue perfusion.  
Hemoglobin correction trials in CKD patients undergoing dialysis were initially promising and 
proved to significantly improve symptoms and quality of life. However, concerns about 
increased risk of cardiovascular events and mortality have evolved following treatment with 
ESA in the CKD population (110-112). As a consequence current CKD guidelines recommend 
hemoglobin levels not to exceed 13 g/dl when treated with ESAs, to prevent excess 
cardiovascular events (113;114). Likewise hemoglobin correction with iron supplement and 
ESA in heart failure patients is promising with proved improved exercise capacity and 
improved hemodynamics (43-45;109). However, no evidence on gain in life expectance 
exists and target hemoglobin level is uncertain. Our data may be important in selecting 
patients that would probably not profit from anemia treatment, thereby guiding a design of 
future clinical trials to investigate the prognostic effect of anemia treatment. 
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Anemia was not necessarily persistent; a high proportion of patients who were anemic at 
baseline had normal hemoglobin levels at follow-up. Likewise, new-onset anemia was 
equally prevalent. The patients with transient anemia did not have significantly higher 
mortality rates compared to patients without anemia at any visit, a finding that is supported 
by Tang et al. (115). New onset anemia is, however, shown to predict outcome in HF patients 
(115;116). After multivariate correction, we could not confirm this, but low number of 
patients in this group gave small statistical power to this analysis. Sustained anemia 
however, strongly predicted mortality and among these patients no interactions with NYHA 
class and GFR were found. 
The ideal hemoglobin level for patients with heart failure is not known and the definition of 
anemia in HF patients is arbitrary as outlined in section 5.1.4. Lower hemoglobin levels in our 
patients with sustained anemia were associated with increased mortality, thus the degree of 
anemia would probably identify patients at especially high risk of mortality. Hemoglobin 
level was not associated with all-cause mortality in patients with no or transient anemia. 
Increased risk of mortality and hospitalization and reduced exercise capacity are found in HF 
patients with hemoglobin levels below 13 g/dl (117;118). In concert with these studies, our 
data did not imply better prognosis with hemoglobin levels exceeding 13 g/dl.   
An interesting observation in our material was the different conclusions drawn when we 
analyzed baseline anemia in the entire population compared to sustained anemia in the 
selected subgroup of the patients completing all visits in the study. Completing all visits was 
independently associated with better survival from the date of the last visit. This might 
reflect that being able to attend subsequent visits is an independent marker of better health. 
Randomized clinical trials are considered the gold standard of clinical evidence. However, if 
being able to participate in clinical trials is an independent variable of better health, it is 
uncertain whether the conclusions drawn from such studies would be applicable for an 
unselected outpatient cohort.   
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5.2.3 Paper III  
5.2.3.1 Prognostic utility of BNP/NT-ProBNP in patients with HF and renal 
dysfunction 
Renal dysfunction is considered a confounding factor when evaluating the level of natriuretic 
peptides in HF patients. The association between BNP/Pro-BNP and renal function is 
complex. Patient with CKD tend to have higher atrial pressure, systemic blood pressure, 
ventricular mass and more vascular disease than the general population, all of which could 
lead to higher “true” physiological levels of natriuretic peptides (78). On the other hand, 
decreased renal filtration and renal clearance by NPR-C and NEP within renal tissue might 
increase the levels. Furthermore decreased renal responsiveness to BNP in the kidneys may 
contribute to the higher levels observed in CKD patients (78).  
Our study confirmed the strong association between renal dysfunction and level of BNP/NT-
ProBNP. The majority of patients with eGFR ≤ 60 ml/min/1.73 m2 had BNP/NT-ProBNP levels 
in the highest BNP group (59 %). Earlier studies have demonstrated the impaired prognosis 
in HF patients with renal dysfunction and elevated natriuretic peptides (119;120). In contrast 
to these studies, the main focus in paper III was on the patients with renal dysfunction and 
still not levels of BNP/NT-proBNP in the highest BNP group, accounting for 41 % of the 
patients with renal dysfunction. Interestingly, these patients presented equal 2-year all-
cause mortality as patients without renal dysfunction and with comparable BNP/NT-ProBNP 
levels. Thus, BNP/NT-ProBNP predicted 2-year mortality irrespective of renal function in 
these patients. This has to our knowledge not previously been highlighted. In the discussion 
whether impaired renal function is a confounding variable when evaluating BNP/NT-ProBNP 
in HF patients, this could be an important observation. Our study was not designed to decide 
if the strong association between renal dysfunction and levels of natriuretic peptides is a 
consequence of increased production, decreased clearance or both. However, our data 
stated that BNP/NT-ProBNP was an important prognostic marker also in patients with 
impaired renal function.  Furthermore, our data could propose that BNP/NT-ProBNP should 
be interpreted as the current burden of heart and vascular disease at the time of 
investigation also in CKD patients, without considering the actual mechanism behind. 
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We observed an exponentially increasing hazard of all-cause mortality by time in the 
patients with impaired renal function and within BNP group 1-3. Beyond two years of follow-
up the initial BNP/ProBNP level did not predict mortality in patients with renal dysfunction. 
As BNP/NT-ProBNP are short acting hormones, reflecting primarily actual myocardial wall 
stress (78;121), it would not be surprising that they primarily predicted shorter term 
prognosis. The exponentially increasing hazard of all-cause mortality by time in CKD patients 
may provide insight in the increased susceptibility to progressive heart and cardiovascular 
disease in patients with CKD (29;122;123). Consecutive measurements of natriuretic 
peptides would have been interesting. Then, it would be possible to evaluate progression of 
HF and changes in BNP/NT-ProBNP levels in patients with renal dysfunction compared to 
patients with preserved GFR, and thereby investigate whether changes in BNP/NT-ProBNP 
during follow-up would yield prognostic information in patients with renal dysfunction. This 
question is to our knowledge not addressed yet and should be investigated in a future 
prospective trial. 
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6. Summary 
Renal dysfunction is common in outpatients with heart failure as nearly half the patients 
admitted to Norwegian outpatient HF clinics had eGFR<60 ml/min/1.73 m2. GFR was a strong 
independent predictor of all-cause mortality and preserving renal function during treatment 
and follow-up, ought to be important for every physician dealing with heart failure patients. 
The relationship between GFR and HF is not fully understood, but hemodynamic issues and 
neuroendocrine activation seem important. Spironolactone and higher doses of loop 
diuretics were associated with worse renal function at baseline and deterioration of renal 
function during follow-up, while RAAS- and β-blocking drugs were neutral concerning kidney 
function. While our registry data could not determine causal effect, they indicate that use of 
loop diuretics and spironolactone should be carefully evaluated as they are associated with 
negative effect on renal function, and thereby may worsen prognosis. Prospective 
randomized trials would possibly have answered this question, but such studies will probably 
never be undertaken. 
Anemia was prevalent, 24% of the patients presented with anemia at baseline. Anemia was 
independently associated with impaired GFR and increasing NYHA class. Baseline anemia 
was a strong independent marker of prognosis, but was not a predictor of all-cause mortality 
among the patients with the worst prognosis i.e. patients with severe renal dysfunction and 
advanced heart failure. Anemia was not necessarily persistent, transient and new-onset 
anemia did not predict worse prognosis in our study in contrast to sustained anemia. Clinical 
trials are needed to investigate the effect of anemia treatment on all-cause mortality. Our 
data suggest that the patients with preserved GFR and lower NYHA class may benefit the 
most from anemia treatment.    
Renal dysfunction has been considered a confounding factor in the interpretation of 
natriuretic peptides in HF patients, thereby limiting their use in daily practice. Our study 
confirmed the strong association between renal dysfunction and level of BNP/NT-ProBNP. 
However, as BNP/NT-ProBNP predicted 2-year mortality irrespective of renal function in 
patients within the lower three BNP groups, our data might indicate that the natriuretic 
peptides should be interpreted the same way in patients with renal dysfunction as in 
patients with preserved renal function. BNP is released from cardiac myocytes 
predominantly as a result of myocyte stretch and cardiovascular diseases associated with 
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renal dysfunction are prone to increase cardiac work load. Therefore, BNP/NT-ProBNP levels 
might reflect current burden of cardiovascular disease in patients with renal dysfunction. 
Evaluation of both BNP/NT-ProBNP and GFR in patients with HF might prove valuable in the 
evaluation of both short- and long-term prognosis. 
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7. Future perspectives 
The prevalence of HF is high and may continue to rise in the following years as the number 
of elderly is rising. Traditional variables used to identify HF patients with poor prognosis have 
been higher age, low LVEF, ischemic etiology of HF, higher NYHA class and hyponatremia 
among many others (1). In our study; GFR, anemia and the natriuretic peptides together 
with increasing age and NYHA class were the most important independent prognostic factors 
concerning all-cause mortality. LVEF was not an independent risk factor of all-cause 
mortality in our analyses, neither was ischemic heart disease. Traditional prognostic markers 
were established in an era where heart failure patients may have been different from 
today’s HF population. Treatment of coronary heart disease, the main cause of HF, has 
improved during the last decades, while the prevalence of hypertension and chronic 
diseases, like CKD, that predispose to HF is increasing. Thus, the etiology of HF might be 
changing. Furthermore, treatment possibilities in patients having or being at risk of HF have 
evolved. Traditional prognostic markers may therefore fail to alert the clinicians about which 
patients are at high risk of impaired prognosis. Predictive factors for the prognosis in HF 
patients ought to be updated and reconsidered in the future guidelines. 
Furthermore, current knowledge of HF treatment is founded on studies of HF patients with 
reduced LVEF and relative lack of comorbidities. A suspected change in etiology of HF, 
growing number of elderly with HF and increasing number of HF patients living with 
comorbid chronic diseases would make these studies less representative for the real life HF 
population. No therapies have proven to alter the natural history of HF patients with 
preserved LVEF, and likewise there is lack of evidence of effective therapies in HF patients 
with comorbidities like renal dysfunction. Randomized controlled trials in these patients 
would be of great interest. Such studies are however, demanding and it is not likely that 
trials of currently established therapies will ever occur in additional groups of HF patients. 
Well-designed observational registry studies might therefore be increasingly important, and 
lead to improved treatment and outcome of HF patients in the future. Establishing, and 
continuously improving, well-functioning national and international HF registries should be 
given priority and be a part of the planning of healthcare.  
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8. Further research 
As demonstrated, the cardiorenal associations in patients with heart failure are complex and 
not fully understood. Diabetes mellitus (DM) is a major risk factor of both cardiac and renal 
disease and the prevalence of DM is rising in the overall population. As a consequence 
increasing numbers of HF patients will have DM in the future. DM is considered an important 
factor of poor outcome in patients with HF, but there are no robust data in patients with HF 
with preserved LVEF and non-ischemic heart disease. Furthermore, treatment of patients 
with combined HF, renal dysfunction and DM needs to be evaluated. The Norwegian Heart 
Failure Registry may provide insight into the prevalence and prognostic importance of DM in 
HF patientsand current HF treatment options may be assessed in relationship to the 
presence of DM. 
Uric acid is associated with poor prognosis in patients with HF and is associated with renal 
function, use of diuretics and DM. Whether uric acid is a mediator or marker of disease is 
debated, but a growing number of reports gives theoretical rationale that uric acid might 
contribute to disease progression in HF patients. Data from our registry might give further 
insight into this intricate question. 
Health related quality of life is given increasingly attention as validated forms are developed 
to measure this dimension of health. Self-perceived quality of life is important for the 
patients and quality of life should most likely be routinely assessed regulary in HF patients. 
Our registry can provide data of quality of life using a validated tool, and this might expand 
the horizon of cardiorenal associations.     
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9. Errata list 
Paper I, Heading Table 3: “…dependent variable Δ New York Heart Association…” was a 
misprint and should be “…dependent variable Δ estimated glomerular filtration 
rate….” 
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